Evobrutinib, promising BTK inhibitor

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
DIM
Family Elder
Posts: 659
Joined: Thu Feb 28, 2008 3:00 pm
Location: GREECE
Contact:
Contact DIM

Evobrutinib, promising BTK inhibitor

Post by DIM »

https://www.merckgroup.com/en/news/evob ... -2022.html
Top
User avatar
DIM
Family Elder
Posts: 659
Joined: Thu Feb 28, 2008 3:00 pm
Location: GREECE
Contact:
Contact DIM

Re: Evobrutinib, promising BTK inhibitor

Post by DIM »

Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies:

https://www.emdgroup.com/en/news/evobru ... redirect=1
Top
Post Reply

Return to “Drug Pipeline”